Study programme 2021-2022 | Français | ||
Drugs & Strategies for Cancer Treatment - Part 2 | |||
Learning Activity |
Code | Lecturer(s) | Associate Lecturer(s) | Subsitute Lecturer(s) et other(s) | Establishment |
---|---|---|---|---|
M-ANBC-303 |
|
|
Language of instruction | Language of assessment | HT(*) | HTPE(*) | HTPS(*) | HR(*) | HD(*) | Term |
---|---|---|---|---|---|---|---|
Anglais | Anglais | 5 | 0 | 0 | 0 | 0 | Q1 |
Content of Learning Activity
This course will develop the systemic treatment of cancer including chemotherapy, hormone therapy, targeted therapies (against signaling pathways and mutations), and immunotherapy. Cancer chemotherapy uses drugs that interfere with cell growth leading to cell death (cytotoxic drugs) or stopping cell proliferation (cytostatic drugs). This course will also discuss the importance of multidrug therapy. In the context of integrative oncology, the coordination of care between the pharmacist, the doctor and the hospital is important. The efficacy of anticancer treatments and the associated adverse effects will be discussed, in particular concerning the dermatological toxicity of oncological treatments. Finally, the role of pharmacists in supportive care will be presented.
Required Learning Resources/Tools
Not applicable
Recommended Learning Resources/Tools
Not applicable
Other Recommended Reading
Not applicable
Mode of delivery
Type of Teaching Activity/Activities
Evaluations
The assessment methods of the Learning Activity (AA) are specified in the course description of the corresponding Educational Component (UE)